September 4, 2019

MPM’s Todd Foley Discusses Acquisition of Semma Therapeutics in WSJ Pro VC “Vertex Makes Another Aggressive Purchase With Semma”

Todd Foley, MPM Managing Director comments that MPM portfolio company Semma Therapeutics – which aims to develop cell therapy cures for Type 1 diabetes and possibly disrupt the diabetes marketplace — had planned to raise a large financing before going public, but Vertex strongly pursued the company resulting in an $950M cash acquisition. (Full article available to WSJ Pro VC Subscribers only)